Close Menu

NEW YORK – Israeli precision oncology and proteomics startup OncoHost said on Tuesday it has raised $8 million in a Series B funding round, led by investment platform OurCrowd.

The company uses proteomic analysis combined with machine learning on patient blood samples to better understand their response to therapy and detect signs of resistance to treatment through the company's Prophet platform. The funding will be used to finance OncoHost's clinical trials, open a US-based affiliate, and launch Prophet.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.